Last reviewed · How we verify

HU-014 — Competitive Intelligence Brief

HU-014 (HU-014) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Telomerase inhibitor. Area: Oncology.

phase 3 Telomerase inhibitor Telomerase Oncology Biologic Live · refreshed every 30 min

Target snapshot

HU-014 (HU-014) — Huons Co., Ltd.. HU-014 is a synthetic oligonucleotide that acts as a telomerase inhibitor.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
HU-014 TARGET HU-014 Huons Co., Ltd. phase 3 Telomerase inhibitor Telomerase
Etakridin ETHACRIDINE marketed ethacridine Telomerase reverse transcriptase, Reverse transcriptase, Reverse transcriptase/RNaseH
telomerase peptide vaccine GV1001 telomerase peptide vaccine GV1001 Royal Liverpool University Hospital phase 3 Telomerase
allovectin-7/dacarbazine allovectin-7/dacarbazine Vical phase 3 DNA vaccine, chemotherapy Telomerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Telomerase inhibitor class)

  1. Huons Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). HU-014 — Competitive Intelligence Brief. https://druglandscape.com/ci/hu-014. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: